Search Results Label

Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.

https://www.seqirus.com/expertise/influenza

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.com/expertise

Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market

https://www.seqirus.com/news/seqirus-begins-shipping-influenza-vaccines-to-us-market

This EU Flu Day, Seqirus confirms record number of influenza vaccines delivered across Europe to meet increased demand

https://www.seqirus.com/news/eu-flu-day-seqirus-confirms-influenza-vaccines-delivered-across-eu

First adjuvanted quadrivalent influenza vaccine receives EU approval

https://www.seqirus.com/news/first-adjuvanted-quadrivalent-influenza-vaccine--receives-eu-approval

Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.

https://www.seqirus.com/manufacturing/technologies

Understand our aim to develop the next generation of influenza vaccines and how we're working to unite product platforms across the globe.

https://www.seqirus.com/manufacturing/technical-development

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news/seqirus-receives-canadian-approval

Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.com/expertise/influenza/pandemic-response-solutions

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news/new-data-demonstrate-that-fluad-reduces-hospitalization-risk-for-adults-65